RMC-9805 is a small molecule commercialized by Revolution Medicines, with a leading Phase I program in Colorectal Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RMC-9805’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for RMC-9805 is expected to reach an annual total of $108 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RMC-9805 Overview
RMC-9805 is under development for the treatment of solid tumor, pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer. It is administered through oral route. The drug candidate acts by targeting KRAS G12D mutation. The drug candidate is being developed based on tri-complex technology.
Revolution Medicines Overview
Revolution Medicines is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. The company’s pipeline products include RMC-6236 an investigational, oral, RAS(ON) multi-selective non-covalent inhibitor designed to treat pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and other solid tumors; and RMC-6291 and is an investigational, oral, RAS (ON) G12C and G12D selective covalent inhibitors that target solid tumors and non-small cell lung cancer. Its preclinical RAS(ON) mutant-selective inhibitors and RAS companion inhibitors comprise RMC-5127, RMC-0708, RMC-8839, RMC-4630 and RMC-5552. The company operates through its subsidiaries in the US and the UK. Revolution Medicines is headquartered in Redwood City, California, the US.
The company reported revenues of (US Dollars) US$11.6 million for the fiscal year ended December 2023 (FY2023), a decrease of 67.3% over FY2022. The operating loss of the company was US$487.2 million in FY2023, compared to an operating loss of US$258.3 million in FY2022. The net loss of the company was US$436.4 million in FY2023, compared to a net loss of US$248.7 million in FY2022.
For a complete picture of RMC-9805’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
